I am going to live, i hope you do to. My deepest desire is that the life I seek is joyful and rewarding. Maybe together we can make this planet better than we found it. That way when we exhale our last exhale we can smile and meet our destiny, our God in peace.
Major pain this afternoon in bathroom, stopping 500mg xeloda daily, even a week of chemo maybe to much. I have added a few drugs this week, undoing these and seeking gut stability.
I am allowed a 10 minute spot to speak at the gcmaf conference in dubia, i am honoured. the immunotherapy revolution is gaining momentum, we need more patient successes, i do. contact me with your story. I should have packed a suit. I am what I am.
Subscribed to science. Why did i wait so long. having the magazines sent home for kids, i get the online updates. so much more science based research papers. i am thinking of applying for my phd in cancer research with immunotherapies of course.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2900928/ DIET AND KETOGENIC AND IMMUNE
These studies suggest that within personal microbiomic datasets, we will be able to identify genetic biomarkers of discrete functions. Inference of function from these biomarkers should provide predictive power in determining how an individual’s microbiota will respond to changes in diet and other interventions.
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Disruption of β-glucuronidase activity is also demonstrated in bacterial species beyond E. coli (Fig. 3D). Taken together, the data presented here strongly support the hypothesis that microbial β-glucuronidases can be inhibited to prevent the GI production of toxic CPT-11 metabolites. However, full pharmacokinetic studies demonstrating, for example, a reduction in GI SN-38G levels or improved CPT-11 efficacy will be required to unambiguously prove this hypothesis. In addition, the breadth of inhibitor efficacy on human GI bacteria requires further assessment. Still, these initial results involving the oral dosing of an unmodified lead compound are highly promising. If successfully translated to humans, leads like those described here could allow dose intensification of CPT-11, enabling studies of whether efficacy could be improved in relevant human cancers by reducing one of the current dose-limiting side effects. The strategy of selective targeting of an enzyme present in bacterial symbiotes to address a specific clinical problem could potentially be applied more broadly as we deepen our understanding of the essential and dynamic roles that commensal bacteria play in promoting human health.So if your colorectal on irenotecan, read the above and cry, your guts getting screwed in black and white. Potential ways to minise gut damage, i would if i were you. So your guts destroyed by your treatment, hello, so is your immune system, think wisely dear friends.
http://www.cancerresearchuk.org/cancer-info/news/archive/cancernews/2013-11-21-Gut-bacteria-control-response-to-cancer-treatments
"This whole area is relatively unexplored at the moment, and we look forward to seeing more research in the future that helps us to understand the role bacteria play in cancer and its treatment," she added.
Study
http://onlinelibrary.wiley.com/doi/10.1002/stem.150430/pdf injecting stems to thymus to boost lymphocytes
http://www.lab.anhb.uwa.edu.au/mb140/CorePages/Lymphoid1/Lymph1.htm excellent
http://www.sciencemag.org/content/342/6161/967.full.pdf